Volume 18, Number 2—February 2012
Dispatch
Multiorgan Dysfunction Caused by Travel-associated African Trypanosomiasis
Table 2
Month of report | ProMED-mail archive no. | Nationality of patient | Travel activity | Area visited |
---|---|---|---|---|
September | 20100915.3338 | Zambian | Visiting game ranch | South Luangwa Valley, Zambia |
20100915.3338 | American | Hunting safari | South Luangwa Valley, Zambia | |
October† | 20101022.3833 | British | Camping safari | South Luangwa National Park, Lower Zambez National Park, Kafu National Park, Zambia |
20101022.3833 | British | Visiting national park | Mana Pool National Park, Zimbabwe (bordering Zambia) | |
November | 20101111.4093 | South African national of Scandinavian origin | Hiking | Luangwa River area, Zambia |
*Reports in (6). Since the start of 2005, 11 other cases of T. b. rhodesiense infection in travelers have been reported in ProMED-mail; those cases were acquired in Uganda (1), Tanzania (3), and Malawi (7).
†Case presented in this report.
References
- Welburn SC, Picozzi K, Fèvre EM, Coleman PG, Odiit M, Carrington M, Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet. 2001;358:2017–9. DOIPubMedGoogle Scholar
- Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375:148–59. DOIPubMedGoogle Scholar
- Abramowicz M. Drugs for parasitic infections. In: Abramowicz M, editor. The medical letter on drugs and therapeutics. New Rochelle (NY): The Medical Letter, Inc; 2000. p. 1–12.
- Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol. 2008;64:116–26. DOIPubMedGoogle Scholar
- Gautret P, Clerinx J, Caumes E, Simon F, Jensenius M, Loutan L, Imported human African trypanosomiasis in Europe, 2005–2009. Euro Surveill. 2009;14:pii:19327. PubMedGoogle Scholar
- ProMED-mail. Archive nos. 20100915.3338, 20101022.3833, and 20101111.4093 [cited 2011 Sep 22]. http://www.promedmail.org
- Sinha A, Grace C, Alston WK, Westenfeld F, Maguire JH. African trypanosomiasis in two travelers from the United States. Clin Infect Dis. 1999;29:840–4. DOIPubMedGoogle Scholar
- Reincke M, Arlt W, Heppner C, Petzke F, Chrousos GP, Allolio B. Neuroendocrine dysfunction in African trypanosomiasis. Ann N Y Acad Sci. 1998;840:809–21. DOIPubMedGoogle Scholar
- Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology. 2010;137:1987–94. DOIPubMedGoogle Scholar
- Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol. 2009;211:16–22. DOIPubMedGoogle Scholar
- World Health Organization. Control and surveillance of African trypanosomiasis. Report of a WHO expert committee. WHO Technical Report Series. 1998;881:I–VI, 1–114.
- Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, Nolan DP, Lins L, Van Den Abbeele J, Apolipoprotein L–I is the trypanosome lytic factor of human serum. Nature. 2003;422:83–7. DOIPubMedGoogle Scholar
- Pays E, Vanhollebeke B. Human innate immunity against African trypanosomes. Curr Opin Immunol. 2009;21:493–8. DOIPubMedGoogle Scholar
- Vanhollebeke B, Truc P, Poelvoorde P, Pays A, Joshi PP, Katti R, Human Trypanosoma evansi infection linked to a lack of apolipoprotein L–I. N Engl J Med. 2006;355:2752–6. DOIPubMedGoogle Scholar
1Current affiliation: Worthing Hospital, Worthing, UK.
Page created: January 24, 2012
Page updated: January 24, 2012
Page reviewed: January 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.